Current status of the Maze procedure for the treatment of atrial fibrillation

Since the first patient underwent the Maze procedure on September 25, 1987, 346 patients have undergone this operation for the treatment of atrial fibrillation. The procedure was designed as an open-heart operation performed through a median sternotomy. It underwent 2 major modifications relatively...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Seminars in thoracic and cardiovascular surgery 2000-01, Vol.12 (1), p.15-19
Hauptverfasser: Cox, J L, Ad, N, Palazzo, T, Fitzpatrick, S, Suyderhoud, J P, DeGroot, K W, Pirovic, E A, Lou, H C, Duvall, W Z, Kim, Y D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 19
container_issue 1
container_start_page 15
container_title Seminars in thoracic and cardiovascular surgery
container_volume 12
creator Cox, J L
Ad, N
Palazzo, T
Fitzpatrick, S
Suyderhoud, J P
DeGroot, K W
Pirovic, E A
Lou, H C
Duvall, W Z
Kim, Y D
description Since the first patient underwent the Maze procedure on September 25, 1987, 346 patients have undergone this operation for the treatment of atrial fibrillation. The procedure was designed as an open-heart operation performed through a median sternotomy. It underwent 2 major modifications relatively early in the series, evolving into the so-called Maze-III procedure, which has been used exclusively since April 16, 1992. Since that time, the Maze-III procedure has been adapted to allow it to be done by minimally invasive techniques. In addition, we recently performed the entire procedure in 2 patients without the use of cardiopulmonary bypass. The operative mortality rate has remained at 2% to 3%. This includes patients undergoing concomitant high-risk cardiac surgical procedures and all re-do cases. The overall success rate in curing atrial fibrillation has been 99%. The procedure itself has been shown to cause no permanent damage to the sinus node. The left atrium has been documented to function long-term postoperatively in 93% of patients and the right atrium functions in 99% of patients. The Maze-III procedure remains the surgical procedure of choice for the treatment of medically refractory atrial fibrillation.
doi_str_mv 10.1016/s1043-0679(00)70011-6
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71013817</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71013817</sourcerecordid><originalsourceid>FETCH-LOGICAL-c340t-4f77fd5bde82beb552c6a34b16a988dae5fa5156e01de8caaba5ffafa3fd5c473</originalsourceid><addsrcrecordid>eNpNkD1PwzAQhj2AaCn8BFAmBEPgXMd2OqKKL6kVAzBbF-csgpKm2M4Avx6nRYjppFfPe3d6GDvjcM2Bq5vAoRA5KL24BLjSAJzn6oBN_-IJOw7hA2DOtRBHbMJBF2rB9ZStl4P3tIlZiBiHkPUui--UrfGbsq3vLdWDp8z1fhdHTxi7EU8cRt9gm7mm8k3bYmz6zQk7dNgGOv2dM_Z2f_e6fMxXzw9Py9tVbkUBMS-c1q6WVU3lvKJKyrlVKIqKK1yUZY0kHUouFQFPiEWsUDqHDkVq2UKLGbvY700vfg4UoumaYCl9saF-CEYnLaLkIyj3oPV9CJ6c2fqmQ_9lOJjRnXkZJZlRkgEwO3dGpd7574Gh6qj-19qLEz8Fwm5S</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71013817</pqid></control><display><type>article</type><title>Current status of the Maze procedure for the treatment of atrial fibrillation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Cox, J L ; Ad, N ; Palazzo, T ; Fitzpatrick, S ; Suyderhoud, J P ; DeGroot, K W ; Pirovic, E A ; Lou, H C ; Duvall, W Z ; Kim, Y D</creator><creatorcontrib>Cox, J L ; Ad, N ; Palazzo, T ; Fitzpatrick, S ; Suyderhoud, J P ; DeGroot, K W ; Pirovic, E A ; Lou, H C ; Duvall, W Z ; Kim, Y D</creatorcontrib><description>Since the first patient underwent the Maze procedure on September 25, 1987, 346 patients have undergone this operation for the treatment of atrial fibrillation. The procedure was designed as an open-heart operation performed through a median sternotomy. It underwent 2 major modifications relatively early in the series, evolving into the so-called Maze-III procedure, which has been used exclusively since April 16, 1992. Since that time, the Maze-III procedure has been adapted to allow it to be done by minimally invasive techniques. In addition, we recently performed the entire procedure in 2 patients without the use of cardiopulmonary bypass. The operative mortality rate has remained at 2% to 3%. This includes patients undergoing concomitant high-risk cardiac surgical procedures and all re-do cases. The overall success rate in curing atrial fibrillation has been 99%. The procedure itself has been shown to cause no permanent damage to the sinus node. The left atrium has been documented to function long-term postoperatively in 93% of patients and the right atrium functions in 99% of patients. The Maze-III procedure remains the surgical procedure of choice for the treatment of medically refractory atrial fibrillation.</description><identifier>ISSN: 1043-0679</identifier><identifier>DOI: 10.1016/s1043-0679(00)70011-6</identifier><identifier>PMID: 10746917</identifier><language>eng</language><publisher>United States</publisher><subject>Atrial Fibrillation - mortality ; Atrial Fibrillation - physiopathology ; Atrial Fibrillation - surgery ; Cardiac Surgical Procedures - methods ; Cardiac Surgical Procedures - mortality ; Electrocardiography ; Heart Atria - physiopathology ; Heart Atria - surgery ; Heart Conduction System - physiopathology ; Heart Conduction System - surgery ; Heart Rate ; Humans ; Minimally Invasive Surgical Procedures ; Patient Selection ; Survival Rate ; Treatment Outcome</subject><ispartof>Seminars in thoracic and cardiovascular surgery, 2000-01, Vol.12 (1), p.15-19</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c340t-4f77fd5bde82beb552c6a34b16a988dae5fa5156e01de8caaba5ffafa3fd5c473</citedby><cites>FETCH-LOGICAL-c340t-4f77fd5bde82beb552c6a34b16a988dae5fa5156e01de8caaba5ffafa3fd5c473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10746917$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cox, J L</creatorcontrib><creatorcontrib>Ad, N</creatorcontrib><creatorcontrib>Palazzo, T</creatorcontrib><creatorcontrib>Fitzpatrick, S</creatorcontrib><creatorcontrib>Suyderhoud, J P</creatorcontrib><creatorcontrib>DeGroot, K W</creatorcontrib><creatorcontrib>Pirovic, E A</creatorcontrib><creatorcontrib>Lou, H C</creatorcontrib><creatorcontrib>Duvall, W Z</creatorcontrib><creatorcontrib>Kim, Y D</creatorcontrib><title>Current status of the Maze procedure for the treatment of atrial fibrillation</title><title>Seminars in thoracic and cardiovascular surgery</title><addtitle>Semin Thorac Cardiovasc Surg</addtitle><description>Since the first patient underwent the Maze procedure on September 25, 1987, 346 patients have undergone this operation for the treatment of atrial fibrillation. The procedure was designed as an open-heart operation performed through a median sternotomy. It underwent 2 major modifications relatively early in the series, evolving into the so-called Maze-III procedure, which has been used exclusively since April 16, 1992. Since that time, the Maze-III procedure has been adapted to allow it to be done by minimally invasive techniques. In addition, we recently performed the entire procedure in 2 patients without the use of cardiopulmonary bypass. The operative mortality rate has remained at 2% to 3%. This includes patients undergoing concomitant high-risk cardiac surgical procedures and all re-do cases. The overall success rate in curing atrial fibrillation has been 99%. The procedure itself has been shown to cause no permanent damage to the sinus node. The left atrium has been documented to function long-term postoperatively in 93% of patients and the right atrium functions in 99% of patients. The Maze-III procedure remains the surgical procedure of choice for the treatment of medically refractory atrial fibrillation.</description><subject>Atrial Fibrillation - mortality</subject><subject>Atrial Fibrillation - physiopathology</subject><subject>Atrial Fibrillation - surgery</subject><subject>Cardiac Surgical Procedures - methods</subject><subject>Cardiac Surgical Procedures - mortality</subject><subject>Electrocardiography</subject><subject>Heart Atria - physiopathology</subject><subject>Heart Atria - surgery</subject><subject>Heart Conduction System - physiopathology</subject><subject>Heart Conduction System - surgery</subject><subject>Heart Rate</subject><subject>Humans</subject><subject>Minimally Invasive Surgical Procedures</subject><subject>Patient Selection</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>1043-0679</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkD1PwzAQhj2AaCn8BFAmBEPgXMd2OqKKL6kVAzBbF-csgpKm2M4Avx6nRYjppFfPe3d6GDvjcM2Bq5vAoRA5KL24BLjSAJzn6oBN_-IJOw7hA2DOtRBHbMJBF2rB9ZStl4P3tIlZiBiHkPUui--UrfGbsq3vLdWDp8z1fhdHTxi7EU8cRt9gm7mm8k3bYmz6zQk7dNgGOv2dM_Z2f_e6fMxXzw9Py9tVbkUBMS-c1q6WVU3lvKJKyrlVKIqKK1yUZY0kHUouFQFPiEWsUDqHDkVq2UKLGbvY700vfg4UoumaYCl9saF-CEYnLaLkIyj3oPV9CJ6c2fqmQ_9lOJjRnXkZJZlRkgEwO3dGpd7574Gh6qj-19qLEz8Fwm5S</recordid><startdate>200001</startdate><enddate>200001</enddate><creator>Cox, J L</creator><creator>Ad, N</creator><creator>Palazzo, T</creator><creator>Fitzpatrick, S</creator><creator>Suyderhoud, J P</creator><creator>DeGroot, K W</creator><creator>Pirovic, E A</creator><creator>Lou, H C</creator><creator>Duvall, W Z</creator><creator>Kim, Y D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200001</creationdate><title>Current status of the Maze procedure for the treatment of atrial fibrillation</title><author>Cox, J L ; Ad, N ; Palazzo, T ; Fitzpatrick, S ; Suyderhoud, J P ; DeGroot, K W ; Pirovic, E A ; Lou, H C ; Duvall, W Z ; Kim, Y D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c340t-4f77fd5bde82beb552c6a34b16a988dae5fa5156e01de8caaba5ffafa3fd5c473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Atrial Fibrillation - mortality</topic><topic>Atrial Fibrillation - physiopathology</topic><topic>Atrial Fibrillation - surgery</topic><topic>Cardiac Surgical Procedures - methods</topic><topic>Cardiac Surgical Procedures - mortality</topic><topic>Electrocardiography</topic><topic>Heart Atria - physiopathology</topic><topic>Heart Atria - surgery</topic><topic>Heart Conduction System - physiopathology</topic><topic>Heart Conduction System - surgery</topic><topic>Heart Rate</topic><topic>Humans</topic><topic>Minimally Invasive Surgical Procedures</topic><topic>Patient Selection</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cox, J L</creatorcontrib><creatorcontrib>Ad, N</creatorcontrib><creatorcontrib>Palazzo, T</creatorcontrib><creatorcontrib>Fitzpatrick, S</creatorcontrib><creatorcontrib>Suyderhoud, J P</creatorcontrib><creatorcontrib>DeGroot, K W</creatorcontrib><creatorcontrib>Pirovic, E A</creatorcontrib><creatorcontrib>Lou, H C</creatorcontrib><creatorcontrib>Duvall, W Z</creatorcontrib><creatorcontrib>Kim, Y D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Seminars in thoracic and cardiovascular surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cox, J L</au><au>Ad, N</au><au>Palazzo, T</au><au>Fitzpatrick, S</au><au>Suyderhoud, J P</au><au>DeGroot, K W</au><au>Pirovic, E A</au><au>Lou, H C</au><au>Duvall, W Z</au><au>Kim, Y D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current status of the Maze procedure for the treatment of atrial fibrillation</atitle><jtitle>Seminars in thoracic and cardiovascular surgery</jtitle><addtitle>Semin Thorac Cardiovasc Surg</addtitle><date>2000-01</date><risdate>2000</risdate><volume>12</volume><issue>1</issue><spage>15</spage><epage>19</epage><pages>15-19</pages><issn>1043-0679</issn><abstract>Since the first patient underwent the Maze procedure on September 25, 1987, 346 patients have undergone this operation for the treatment of atrial fibrillation. The procedure was designed as an open-heart operation performed through a median sternotomy. It underwent 2 major modifications relatively early in the series, evolving into the so-called Maze-III procedure, which has been used exclusively since April 16, 1992. Since that time, the Maze-III procedure has been adapted to allow it to be done by minimally invasive techniques. In addition, we recently performed the entire procedure in 2 patients without the use of cardiopulmonary bypass. The operative mortality rate has remained at 2% to 3%. This includes patients undergoing concomitant high-risk cardiac surgical procedures and all re-do cases. The overall success rate in curing atrial fibrillation has been 99%. The procedure itself has been shown to cause no permanent damage to the sinus node. The left atrium has been documented to function long-term postoperatively in 93% of patients and the right atrium functions in 99% of patients. The Maze-III procedure remains the surgical procedure of choice for the treatment of medically refractory atrial fibrillation.</abstract><cop>United States</cop><pmid>10746917</pmid><doi>10.1016/s1043-0679(00)70011-6</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1043-0679
ispartof Seminars in thoracic and cardiovascular surgery, 2000-01, Vol.12 (1), p.15-19
issn 1043-0679
language eng
recordid cdi_proquest_miscellaneous_71013817
source MEDLINE; Elsevier ScienceDirect Journals
subjects Atrial Fibrillation - mortality
Atrial Fibrillation - physiopathology
Atrial Fibrillation - surgery
Cardiac Surgical Procedures - methods
Cardiac Surgical Procedures - mortality
Electrocardiography
Heart Atria - physiopathology
Heart Atria - surgery
Heart Conduction System - physiopathology
Heart Conduction System - surgery
Heart Rate
Humans
Minimally Invasive Surgical Procedures
Patient Selection
Survival Rate
Treatment Outcome
title Current status of the Maze procedure for the treatment of atrial fibrillation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T05%3A34%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20status%20of%20the%20Maze%20procedure%20for%20the%20treatment%20of%20atrial%20fibrillation&rft.jtitle=Seminars%20in%20thoracic%20and%20cardiovascular%20surgery&rft.au=Cox,%20J%20L&rft.date=2000-01&rft.volume=12&rft.issue=1&rft.spage=15&rft.epage=19&rft.pages=15-19&rft.issn=1043-0679&rft_id=info:doi/10.1016/s1043-0679(00)70011-6&rft_dat=%3Cproquest_cross%3E71013817%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71013817&rft_id=info:pmid/10746917&rfr_iscdi=true